Recently Updated Guidelines
Guidelines for Treatment of Cancer by Type
-
Acute Myeloid Leukemia Version 3.2022
-
Anal Carcinoma Version 1.2023
-
B-Cell Lymphomas Version 1.2023
-
Breast Cancer Version 1.2023
-
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version 2.2023
-
Colon Cancer Version 3.2022
-
Hepatobiliary Cancers Version 5.2022
-
Kidney Cancer Version 4.2023
-
Pediatric Hodgkin Lymphoma Version 1.2023
-
Primary Cutaneous Lymphomas Version 1.2023
-
Rectal Cancer Version 4.2022
-
Small Bowel Adenocarcinoma Version 1.2023
-
T-Cell Lymphomas Version 1.2023
-
Testicular Cancer Version 1.2023
-
NCCN Guidelines with Evidence Blocks - Acute Myeloid Leukemia Version 3.2022
-
NCCN Guidelines with Evidence Blocks - Anal Carcinoma Version 1.2023
-
NCCN Guidelines with Evidence Blocks - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version 2.2023
-
NCCN Guidelines with Evidence Blocks - Hepatobiliary Cancers Version 5.2022
-
NCCN Guidelines with Evidence Blocks - Pediatric Hodgkin Lymphoma Version 1.2023
-
NCCN Guidelines with Evidence Blocks - Primary Cutaneous Lymphomas Version 1.2023
-
NCCN Guidelines with Evidence Blocks - Small Bowel Adenocarcinoma Version 1.2023
-
NCCN Guidelines with Evidence Blocks - T-Cell Lymphomas Version 1.2023
-
NCCN Guidelines with Evidence Blocks - Testicular Cancer Version 1.2023
Guidelines for Detection, Prevention, & Risk Reduction
-
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Version 2.2023
-
Prostate Cancer Early Detection Version 1.2023
Guidelines for Supportive Care
-
Antiemesis Version 1.2023
-
Cancer-Related Fatigue Version 2.2023
-
Hematopoietic Cell Transplantation Version 3.2022
-
Palliative Care Version 1.2023
-
Smoking Cessation Version 3.2022
Guidelines for Specific Populations
-
Adolescent and Young Adult (AYA) Oncology Version 3.2023